Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies

npj Precision Oncology, Год журнала: 2025, Номер 9(1)

Опубликована: Апрель 4, 2025

Язык: Английский

---

Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates

JCO Oncology Practice, Год журнала: 2025, Номер unknown

Опубликована: Май 13, 2025

The advent of next-generation antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), has transformed our understanding human epidermal growth factor receptor 2 (HER2) targetability for breast cancer (BC) treatment. Historically categorized as HER2-positive or HER2-negative on the basis eligibility, this classification evolved significantly over past 5 years. DESTINY-Breast04 trial marked entry anti-HER2 therapies patients with HER2-low BC, while DESTINY-Breast06 demonstrated potential earlier and broader use T-DXd. latter revealed that even minimal HER2 expression in tumors previously classified HER2-0 might be clinically relevant targetable This led to further refinement classification, introducing concepts HER2-ultralow (HER2-0 staining) HER2-null BC without staining). With these findings, most metastatic are currently considered eligible Accurately identifying candidates highlighted limitations current diagnostic practices, immunohistochemistry (IHC)/in situ hybridization assessment. IHC assay, optimized detect high levels protein, faces discriminating finer variations at lower end spectrum. is complicated by heterogeneity expression. To overcome barriers, new approaches may required. Quantitative methods membrane assessment, genomic transcriptomic evaluations HER2, integration artificial intelligence into tissue analysis hold promise under investigation. Additionally, noninvasive strategies, such circulating tumor DNA cells, enable real-time status assessment better patient selection ADC. However, techniques require rigorous validation ensure their clinical utility. evolving landscape underscores need improvement support expanding role ADCs

Язык: Английский

---

Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression

Cancer Treatment Reviews, Год журнала: 2025, Номер 138, С. 102972 - 102972

Опубликована: Май 27, 2025

Язык: Английский

---

Adverse effect of trastuzumab deruxtecan in solid tumours: a systematic review and meta-analysis

Critical Reviews in Oncology/Hematology, Год журнала: 2025, Номер 213, С. 104787 - 104787

Опубликована: Июнь 2, 2025

Язык: Английский

---